glp-1 neurotransmitter Analogues in the Neurobiology of Addiction: Translational Insights and Therapeutic Perspectives Further support for GLP-1R agonists

Monitoring Schedule Serum IGF-1 at baseline and at 8-12 weeks Fasting glucose at baseline and every 3-6 months (GH increases insulin resistance acutely) Thyroid panel at baseline (hypothyroidism blunts IGF-1 response) Blood pressure and fluid retention assessment at each visit The American Association of Clinical Endocrinology (AACE) recommends IGF-1 be kept within the age- and sex-adjusted reference range during any GH-stimulating therapy to minimize risk of adverse effects including fluid retention and glucose intolerance [9]

It appears on WADA's Prohibited List under "Hormone and Metabolic Modulators." International regulatory status varies: the European Medicines Agency (EMA) has not approved AOD-9604, and it is banned or restricted in many countries as an unapproved drug product

This method not only helps with weight loss but also boosts overall health

This progressive decline means that blood pressure medications prescribed at higher body weight may require adjustment to prevent symptomatic hypotension